The Global Fund ARV Tender has granted a deal Cipla to render anti-AIDS medicines, valued at approx. $188.95 million. As per Cipla , deal is effective January 1, 2015 and will run for a period of three years and from the 4Q the financial year 2015, the supplies will commence.
Subhanu Saxena, Cipla’s Managing Director and Global Chief Executive, said in a statement: “We are extremely proud to have won this tender from Global Fund. Cipla has been committed to the cause of HIV/AIDS for over two decades and this tender offers us a great opportunity to make HIV/AIDS treatment accessible to more than 140 countries through Global Fund.”
Moreover, at Cipla’s manufacturing facilities in India, anti-retrovirals (ARV) drugs will be manufactured, as per the several international regulatory agencies green nod.
Subhanu Saxena, Cipla’s Managing Director and Global Chief Executive, said in a statement: “We are extremely proud to have won this tender from Global Fund. Cipla has been committed to the cause of HIV/AIDS for over two decades and this tender offers us a great opportunity to make HIV/AIDS treatment accessible to more than 140 countries through Global Fund.”
Moreover, at Cipla’s manufacturing facilities in India, anti-retrovirals (ARV) drugs will be manufactured, as per the several international regulatory agencies green nod.